Johnson & Johnson (NYSE:JNJ – Get Rating) had its price target decreased by equities research analysts at Citigroup from $210.00 to $205.00 in a research note issued to investors on Tuesday, The Fly reports. Citigroup’s target price would suggest a potential upside of 15.12% from the company’s previous close.
JNJ has been the subject of several other research reports. The Goldman Sachs Group lifted their price target on shares of Johnson & Johnson from $163.00 to $181.00 and gave the company a “neutral” rating in a research note on Tuesday, April 12th. Morgan Stanley lowered their price objective on shares of Johnson & Johnson from $175.00 to $173.00 and set an “equal weight” rating for the company in a research note on Wednesday, April 6th. StockNews.com downgraded shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research note on Saturday, April 30th. Bank of America began coverage on shares of Johnson & Johnson in a research report on Wednesday, March 2nd. They set a “neutral” rating for the company. Finally, Sanford C. Bernstein downgraded shares of Johnson & Johnson from an “outperform” rating to a “market perform” rating and boosted their target price for the company from $180.00 to $183.00 in a research report on Wednesday, March 16th. Four analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $187.86.
Shares of Johnson & Johnson stock opened at $178.08 on Tuesday. The firm has a market cap of $468.60 billion, a price-to-earnings ratio of 24.00, a PEG ratio of 2.92 and a beta of 0.66. The business has a 50-day moving average price of $178.11 and a 200-day moving average price of $170.61. The company has a quick ratio of 1.14, a current ratio of 1.39 and a debt-to-equity ratio of 0.39. Johnson & Johnson has a twelve month low of $155.72 and a twelve month high of $186.69.
In other news, VP Thibaut Mongon sold 23,681 shares of the business’s stock in a transaction dated Thursday, March 17th. The shares were sold at an average price of $176.25, for a total transaction of $4,173,776.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider William Hait sold 29,699 shares of the business’s stock in a transaction dated Thursday, April 21st. The stock was sold at an average price of $183.58, for a total transaction of $5,452,142.42. Following the sale, the insider now directly owns 80,236 shares of the company’s stock, valued at approximately $14,729,724.88. The disclosure for this sale can be found here. Corporate insiders own 0.35% of the company’s stock.
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. 1832 Asset Management L.P. grew its stake in Johnson & Johnson by 5.5% during the 1st quarter. 1832 Asset Management L.P. now owns 3,364,903 shares of the company’s stock valued at $588,191,000 after acquiring an additional 175,084 shares in the last quarter. Power Corp of Canada purchased a new stake in Johnson & Johnson during the 1st quarter valued at about $6,815,000. Hutchens & Kramer Investment Management Group LLC grew its stake in Johnson & Johnson by 4.0% during the 1st quarter. Hutchens & Kramer Investment Management Group LLC now owns 1,811 shares of the company’s stock valued at $323,000 after acquiring an additional 70 shares in the last quarter. Journey Strategic Wealth LLC grew its stake in Johnson & Johnson by 22.3% during the 1st quarter. Journey Strategic Wealth LLC now owns 1,718 shares of the company’s stock valued at $304,000 after acquiring an additional 313 shares in the last quarter. Finally, Maverick Capital Ltd. purchased a new stake in shares of Johnson & Johnson during the 1st quarter valued at approximately $1,060,000. 68.78% of the stock is owned by institutional investors.
About Johnson & Johnson (Get Rating)
Johnson & Johnson researches and develops, manufactures, and sells various products in the healthcare field worldwide. It operates in three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- VMWare Inc: Strong Revenues and Excellent Potential
- Etsy Buy!: Why Etsy Stock is Making a Crafty Comeback
- FIGS, Inc Moves Lower On Analysts’ Downgrades
- Option Care Health Stock is Making a Healthy Pullback
- MarketBeat Podcast: Trading Volatile Markets While Preserving Capital
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.